Expert Danai Dima, MD, reviews results of a retrospective, real-world study of teclistamab in patients with R/R MM who would have been considered ineligible for the MajesTEC-1 trial.
EP. 1: Overview of Teclistamab and its MOA in R/R MM
A description and overview of teclistamab and its mechanism of action.
EP. 2: Patient Characteristics in Real-World Study on Teclistamab
Danai Dima, MD, further explores the patient characteristics in the R/R MM teclistamab real-world study.
EP. 3: The Real-World Effectiveness of Treatment with Teclistamab for Patients with R/R MM
Discussion of the real-world effectiveness of teclistamab in R/R MM and the impact on treatment guidelines and practice.
EP. 4: The Efficacy and Safety data and the Potential Impact on Treatment Guidelines and Practice
Presenting real-world data on the efficacy and safety of teclistamab for R/R MM.
EP. 5: How Do These Data Apply to Community Oncologists?
Explanation of how these data apply to community oncologists.
2 Commerce Drive Cranbury, NJ 08512